Clinical and Experimental Allergy最新文献

{"title":"Impact of Uncontrolled Symptoms on the Health-Related Quality of Life (EQ-5D-5L) of Patients With Allergic Rhinitis: A MASK-air Study","authors":"Rafael José Vieira, Lucas Leemann, Holger J. Schünemann, Luís Filipe Azevedo, João A. Fonseca, Jean Bousquet, Bernardo Sousa-Pinto","doi":"10.1111/cea.14516","DOIUrl":"10.1111/cea.14516","url":null,"abstract":"<p>The impact of allergic rhinitis (AR) on patients' quality of life (QoL) may vary with disease control and comorbidities [<span>1</span>]. Previously, we quantified utilities for different levels of AR control but did not assess the impact of specific symptoms on QoL [<span>2</span>]. In this study, we used EQ-5D-5L to assess the impact of uncontrolled individual symptoms on the QoL of patients with AR.</p><p>A full description of the Methods is available electronically (https://doi.org/10.6084/m9.figshare.25253323.v2). We assessed data from European users of the mHealth app MASK-air [<span>3</span>] between May 2015 and December 2022. These users had self-reported AR, were aged between 16 (or 15 in countries with a lower age of digital consent [<span>4</span>]) and 74 years and had filled-in the full EQ-5D-5L questionnaire and/or the EQ-5D visual analogue scale (VAS) alone.</p><p>MASK-air comprises a daily monitoring questionnaire consisting of (i) VASs assessing the daily impact of ocular, nasal, asthma and global allergy symptoms (0–100 scale, a higher score corresponds to a higher impact of symptoms) and (ii) the EQ-5D VAS (0–100 scale, the higher the value the better the patient is feeling on that day). Additionally, users may opt to respond to the EQ-5D-5L questionnaire, which allows for the computation of utilities [<span>5</span>].</p><p>We computed Spearman correlation coefficients between the EQ-5D utility index score or the EQ-5D VAS and symptom VASs (VASs on eye, nose and asthma symptoms).</p><p>We then categorised each symptom VAS into ‘good’, ‘partial’ and ‘poor’ control [<span>6</span>]. We first studied the association between each symptom VAS and QoL by building mixed-effects linear regression models for each symptom individually. Additionally, to measure which isolated symptoms have the greatest impact on QoL (removing the effect of the remaining symptoms), we performed similar regression analyses restricted to observations with ‘good’ control of the two remaining symptom VASs (e.g., to assess the impact of poor versus good control on VAS Eye, we considered only the observations in which there was a simultaneously good control of VAS Nose and VAS Asthma). We performed this stratified analysis (instead of adjusting for the remaining symptoms in regression models) due to multicollinearity between allergy symptoms and the need to account for interactions in multivariable models (which would render regression coefficients difficult to interpret). Separate analyses were performed considering observations from all patients with AR, patients with AR only or patients with AR+asthma [<span>7</span>].</p><p>We analysed 4008 days (reported by 2424 users) with information on utilities and 82,737 days (reported by 7905 users) with information on the EQ-5D VAS (Table S1).</p><p>We found moderate correlations between utilities and symptom VASs (coefficients from −0.38 to −0.41) or between the EQ-5D VAS and symptom VAS (coefficients from −0.3","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 8","pages":"634-637"},"PeriodicalIF":6.3,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141508452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Between Polysensitisation and Polyallergy, the Difference is Substantial and Must be Clarified","authors":"Giorgio Ciprandi","doi":"10.1111/cea.14526","DOIUrl":"10.1111/cea.14526","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 8","pages":"638-639"},"PeriodicalIF":6.3,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COFAITH and COMFA: A Collective Roadmap for Past and Future Food Allergy Clinical Trials and Observational Research on Interventions","authors":"Jennifer L. P. Protudjer, Daniel Munblit, Christian Apfelbacher, Mary Jane Marchisotto, Emma E. Cook, India Capper, Pablo Rodríguez Del Río, Pasquale Comberiati","doi":"10.1111/cea.14522","DOIUrl":"10.1111/cea.14522","url":null,"abstract":"<p>Traditionally, immunoglobulin E (IgE)–mediated food allergy (FA) management required (near) total avoidance of the known allergen(s) and, for those with a history of, or who are at risk of anaphylaxis, the constant possession of an adrenaline autoinjector [<span>1</span>]. Unsurprisingly, FA-associated behaviours contribute to substantial psychosocial [<span>2, 3</span>] and financial [<span>4</span>] burdens. Recent emerging therapies have contributed to a paradigm shift in FA management, which warrant clinical consideration informed by patient preferences [<span>5</span>]. Such shared decision-making is vital to detecting the most critical outcomes that are meaningful and respectful of individual cultural influences on food consumption. On the contrary, a core outcome set (COS) is defined as ‘an agreed standardised set of outcomes that should be measured and reported, as a minimum, in all clinical trials in specific areas of health or health care’ [<span>6</span>]. Recently, two initiatives aiming at outcome harmonisation published important papers on FA outcomes. The first considered clinical outcomes of efficacy in food allergen immunotherapy trials (COFAITH) [<span>7</span>], whereas the second involved a two-stage e-Delphi to identify core outcomes for FA (COMFA) [<span>8</span>] that ought to be included in FA clinical trials henceforth. Importantly, these initiatives also provide considerable opportunity for discussion on how these core outcomes can, and should be implemented in forthcoming studies.</p><p>COFAITH, a task force of the European Academy of Allergy and Clinical Immunology produced a systematic review, covering FA immunotherapy randomised controlled trials and large case series published until 30 March 2022. This review included a total of 45 papers [<span>7</span>]. COFAITH authors noted that primary outcomes should be clinically relevant, unambiguous and meaningful to patients, and aligned with best practice for the reporting of clinical trials (Table 1). They also considered outcomes in the context of the type of food allergen and found out that peanut allergy immunotherapy trials have a different approach to these definitions compared with milk and egg trials, that normally share similar endpoints. The most frequently reported outcome identified in COFAITH was desensitisation, which was further stratified as at or below the maintenance dose or an increase in threshold or success at end-of-trial oral food challenge. One secondary outcome was sustained unresponsiveness, which is not yet likely widely uptaken, and thus may be less frequently considered an outcome, given that long-term sustained unresponsiveness results are poorer than those seen in the short-term. Similarly, thresholds were inconsistently reported across studies, reflecting variation in food types. For example, thresholds for milk and egg were consistent with amounts in regular servings, whereas thresholds for peanuts were based on 1–2 peanut kernels, whic","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 9","pages":"697-699"},"PeriodicalIF":6.3,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14522","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Health Insurance Status and Quality of Life Among People With Asthma in Kolkata","authors":"Sudipta Nandan, Prasun Haldar, Paige Lacy, Saibal Moitra, Subhabrata Moitra","doi":"10.1111/cea.14524","DOIUrl":"10.1111/cea.14524","url":null,"abstract":"<p>Out-of-pocket expenditure for chronic diseases poses a significant economic burden, especially in low- and middle-income countries such as India [<span>1</span>]. Asthma, affecting one in every 50 people in India, accounts for nearly one-tenth of the global asthma population [<span>2</span>]. According to an estimate, the annual cost of asthma treatment per patient is about $240, totalling approximately $9.41 billion annually in India [<span>3</span>]. Despite numerous health schemes of provincial or federal governments, availability of health insurance from the government or privately owned insurance companies and complementary health insurance for employees in most sectors, nearly 60% of all Indians do not possess any health insurance policies. Moreover, most health insurance schemes do not cover physician consultation at an outpatient clinic. Although the disparity in healthcare coverage is recognised as a factor in the economic burden of asthma, there is a lack of studies on the specific role of health insurance on the health-related quality of life (HRQL) in asthma patients.</p><p>In this cross-sectional study, we recruited 224 mild-to-moderate adult asthma patients from two tertiary healthcare facilities in Kolkata. We collected demographic information, such as age, sex, body mass index (BMI), education, employment, addiction (smoking and alcohol consumption), family type (nuclear/joint) and health insurance (yes/no) by questionnaire. Asthma was physician-diagnosed. Comorbidity was assessed by the Charlson Comorbidity Index (CCI) [<span>4</span>]. Asthma control was assessed by the asthma control test (ACT) and was categorised as well-controlled (score ≥ 20), partially controlled (score 16–19) and poorly controlled (score < 16) as per the established guidelines [<span>5</span>]. HRQL was assessed using the asthma quality-of-life questionnaire (AQLQ) [<span>6</span>]. All questionnaires were self-administered, utilising prevalidated Bengali versions of the ACT and AQLQ. The study was approved by the Human Research Ethics Committee of the Allergy & Asthma Research Centre, Kolkata (CREC-AARC-0027/18), and participants provided signed informed consent. The repository shows the demographic and clinical characteristics of the study participants.</p><p>Descriptive statistics were presented as mean (standard deviation [SD]), median (interquartile range [IQR]) or frequencies (%) as appropriate. We constructed multivariable linear regression models to test the associations between health insurance and AQLQ total and subdomain scores adjusted for age, sex, education, employment status, alcohol consumption and CCI score. We stratified the models by sex and asthma control as specified earlier and compared the estimates between sex and asthma control groups using the Wald test.</p><p>Based on the a priori mean (SD) of the AQLQ total score of 5.24 (0.67) in a previously published report [<span>7</span>], our sample size achieved 100% power to de","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 9","pages":"709-711"},"PeriodicalIF":6.3,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14524","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low CCR3 Expression Is a Marker of Active Disease in Chronic Spontaneous Urticaria","authors":"Crisjana Bellamy, Kristin Chichester, Sarbjit Saini, Eric T. Oliver","doi":"10.1111/cea.14523","DOIUrl":"10.1111/cea.14523","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 9","pages":"703-705"},"PeriodicalIF":6.3,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fractional Exhaled Nitric Oxide Identifies Worse Outcomes in Asthmatics With Mucus Plugging and Bronchial Wall Thickening","authors":"Rory Chan, Chary Duraikannu, Mohamed Jaushal Thouseef, Brian Lipworth","doi":"10.1111/cea.14525","DOIUrl":"10.1111/cea.14525","url":null,"abstract":"<p>Fractional exhaled nitric oxide (FeNO) is a point-of-care breathing test that assesses IL13-mediated airway inflammation which is closely linked to severe asthma exacerbations [<span>1</span>]. Mucus plugging (MP) and bronchial wall thickening (BWT) have been identified as important asthma phenotypes [<span>2, 3</span>] and are, in turn, associated with elevated FeNO [<span>4</span>]. It is unknown, however, whether FeNO is a useful test when investigating asthma patients with MP or BWT.</p><p>We, therefore, performed a cross-sectional review of 55 consecutive patients with Global Initiative for Asthma (GINA) defined moderate-to-severe asthma who had a high-resolution computed tomography (HRCT) scan demonstrating the presence of MP or BWT between January 2019 and June 2023. Two senior thoracic radiologists interpreted all scans as previously described and were blinded to clinical information except for a diagnosis of persistent asthma. Briefly, MP was deemed present if any bronchopulmonary segments contained a fully obstructing plug, with a maximum score of 20 if all segments were obstructed [<span>2</span>]. BWT was considered evident if the wall area (WA) thickness exceeded 50% of the total airway area [<span>3</span>]. Patients were subsequently divided into tertiles according to FeNO.</p><p>FeNO (NIOX VERO, Circassia, UK) was performed according to American Thoracic Society (ATS) guidelines. Spirometry (Micromedical, Chatham, UK) values were obtained in triplicate as per ATS/European Respiratory Society (ERS) guidelines. A prednisolone prescription of 40 mg for at least 5 days in the preceding year constituted one severe asthma exacerbation. The Asthma Control Questionnaire (ACQ) was used to assess symptom control.</p><p>Statistical analysis was performed using SPSS v28 where differences in continuous variables were analysed using independent <i>T</i>-tests or Mann–Whitney <i>U</i>-tests. Categorical variables were analysed using chi-squared tests. A two-tailed alpha error of 0.05 was used to denote statistical significance. Caldicott Guardian approval (IGTCAL10360 and IGTCAL10810+) was obtained before any data collection.</p><p><i>N</i> = 38/55 (69%) and <i>n</i> = 34/55 (62%) patients exhibited a mucus plug score (MPS) ≥1 or WA ≥ 50%, respectively, whilst <i>n</i> = 17/55 (31%) patients exhibited both MPS ≥ 1 and WA ≥ 50%. Patient demographics are presented in Table 1.</p><p>The presence of elevated FeNO was associated with significantly worse forced expiratory volume in 1 s percentage predicted (FEV<sub>1</sub>%) in patients with MP (Table 1). In patients with BWT, more frequent severe exacerbations and worse symptom control was observed in those with higher FeNO (Table 1). Moreover, patients in both groups with raised FeNO exhibited higher blood eosinophils.</p><p>Previous studies have demonstrated greater FeNO levels and worse lung function in asthmatics with MP compared with those without [<span>2</span>]. The present study adds to t","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 9","pages":"706-708"},"PeriodicalIF":6.3,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14525","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Refractory Anaphylaxis: An Overview of Current Guidelines","authors":"Guillaume Pouessel,&nbsp;Timothy E. Dribin,&nbsp;Charles Tacquard,&nbsp;Luciana Kase Tanno,&nbsp;Victoria Cardona,&nbsp;Margitta Worm,&nbsp;Antoine Deschildre,&nbsp;Antonella Muraro,&nbsp;Lene H. Garvey,&nbsp;Paul J. Turner","doi":"10.1111/cea.14514","DOIUrl":"10.1111/cea.14514","url":null,"abstract":"<p>In this review, we compare different refractory anaphylaxis (RA) management guidelines focusing on cardiovascular involvement and best practice recommendations, discuss postulated pathogenic mechanisms underlining RA and highlight knowledge gaps and research priorities. There is a paucity of data supporting existing management guidelines. Therapeutic recommendations include the need for the timely administration of appropriate doses of aggressive fluid resuscitation and intravenous (IV) adrenaline in RA. The preferred second-line vasopressor (noradrenaline, vasopressin, metaraminol and dopamine) is unknown. Most guidelines recommend IV glucagon for patients on beta-blockers, despite a lack of evidence. The use of methylene blue or extracorporeal life support (ECLS) is also suggested as rescue therapy. Despite recent advances in understanding the pathogenesis of anaphylaxis, the factors that lead to a lack of response to the initial adrenaline and thus RA are unclear. Genetic factors, such as deficiency in platelet activating factor-acetyl hydrolase or hereditary alpha-tryptasaemia, mastocytosis may modulate reaction severity or response to treatment. Further research into the underlying pathophysiology of RA may help define potential new therapeutic approaches and reduce the morbidity and mortality of anaphylaxis.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 7","pages":"470-488"},"PeriodicalIF":6.3,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14514","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Infant Atopic Eczema to Prevent Severe Eczema and Food Allergy","authors":"Kiwako Yamamoto-Hanada,&nbsp;Yukihiro Ohya","doi":"10.1111/cea.14515","DOIUrl":"10.1111/cea.14515","url":null,"abstract":"<div>\u0000 \u0000 <p>Early intervention and active management of infant atopic eczema may play a crucial role in limiting eczema severity and preventing the onset of immediate-type food allergy. Eczema management involves education, skincare and medications targeting skin inflammation and barrier repair. Topical corticosteroids are the mainstay of anti-inflammatory therapy, with nonsteroidal options available for some infants. Proactive therapy, addressing subclinical inflammation, is useful for preventing eczema flares, especially in infants with recurrent eczema flares despite reactive therapy. In clinical practice, holistic consideration of overall infant and family health is essential. Providing advice on maternal stress management, nutritional guidance and recommendations for proper sleep and lifestyle is crucial for the well-being of children and their families, not limited to eczema treatment alone.</p>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 9","pages":"669-681"},"PeriodicalIF":6.3,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhaled Corticosteroids Versus Placebo for Stable Chronic Obstructive Pulmonary Disease","authors":"Erin Kamalanathan,&nbsp;Sargam Sharma","doi":"10.1111/cea.14521","DOIUrl":"10.1111/cea.14521","url":null,"abstract":"&lt;p&gt;Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide [&lt;span&gt;1&lt;/span&gt;]. It is a chronic noncurable condition, which is defined by progressive respiratory symptoms and airflow limitation. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024's guidelines suggest a short-acting beta 2 agonist (SABA) or a long-acting beta 2 agonists (LABA) initially with the addition of a long-acting muscarinic antagonist as necessary. Inhaled corticosteroids (ICS) are considered if a patient falls into Group E. The criteria for Group E include if patients have ≥2 moderate exacerbations or ≥1 leading to hospitalisation and if their eosinophils ≥300 cells per microliter. If a patient has concomitant asthma, patients should be treated following the asthma treatment guideline, so the use of an ICS is mandatory [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Disclaimer: This is an abstract of a Cochrane review ‘Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease’ published in &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2023 Issue 3 10.1002/14651858.cd002991.pub4. Accessed 9 May 2024 (see www.cochranelibrary.com for information). Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the more recent version of the review.&lt;/p&gt;&lt;p&gt;Thirty-six primary studies with 23,139 participants met the inclusion criteria. Mean age ranged from 52 to 67 years, and females were 0%–46% of participants. Studies recruited across the severities of COPD. Seventeen studies were of duration longer than 3 months and up to 6 months and 19 studies were of duration longer than 6 months. We judged the overall risk of bias as low.&lt;/p&gt;&lt;p&gt;Long-term (more than 6 months) use of ICS as monotherapy reduced the mean rate of exacerbations in those studies where pooling of data was possible (generic inverse variance analysis: rate ratio 0.88 exacerbations per participant per year, 95% confidence interval (CI) 0.82–0.94; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 48%, 5 studies, 10,097 participants; moderate-certainty evidence; pooled means analysis: mean difference (MD) −0.05 exacerbations per participant per year, 95% CI −0.07 to −0.02; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 78%, 5 studies, 10,316 participants; moderate-certainty evidence). ICS slowed the rate of decline in quality of life, as measured by the St George's Respiratory Questionnaire (MD −1.22 units/year, 95% CI −1.83 to −0.60; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 0%; 5 studies, 2507 participants; moderate-certainty evidence; minimal clinically importance difference 4 points). There was no evidence of a difference in all-cause mortality in people with COPD (odds ratio (OR) 0.94, 95% CI 0.84–1.07; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 0%; 10 studies, 16,636 participants; moderate-certainty evidence). Long-term use of ICS reduced the rate of decline in FEV1 in people with COPD (generic inverse variance analysis: MD 6.31 mL/year benefit, 95% CI 1.76–10.85; &lt;i&gt;I&lt;/","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 7","pages":"455-458"},"PeriodicalIF":6.3,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14521","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Study of Vitamin D Status and Risk of Developing Specific Immunoglobulin E During Mid-Childhood","authors":"George Doumat,&nbsp;Joumane El Zein,&nbsp;Geneva D. Mehta,&nbsp;Zhaozhong Zhu,&nbsp;Ying Shelly Qi,&nbsp;Janice A. Espinola,&nbsp;Ashley F. Sullivan,&nbsp;Kohei Hasegawa,&nbsp;Carlos A. Camargo Jr","doi":"10.1111/cea.14511","DOIUrl":"10.1111/cea.14511","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 8","pages":"627-630"},"PeriodicalIF":6.3,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}